Get the Stockscreener App
0.8249
2.61%
-0.0221
Talphera Inc stock is traded at $0.8249, with a volume of 34,921.
It is down -2.61% in the last 24 hours and up +3.53% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.847
Open:
$0.8301
24h Volume:
34,921
Relative Volume:
0.17
Market Cap:
$41.29M
Revenue:
$28,000
Net Income/Loss:
$-14.36M
P/E Ratio:
-2.2725
EPS:
-0.363
Net Cash Flow:
$-11.36M
1W Performance:
+4.42%
1M Performance:
+3.53%
6M Performance:
-25.68%
1Y Performance:
+67.15%
1-Day Range:
$0.81
$0.847
1-Week Range:
$0.739
$0.8597
52-Week Range:
$0.38
$1.57
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.8249 | 42.39M | 28,000 | -14.36M | -11.36M | -0.363 |
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.07 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.665 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.19 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
580.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-05-19 | Resumed | Credit Suisse | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Outperform |
| Apr-24-19 | Resumed | B. Riley FBR | Buy |
| Feb-15-19 | Initiated | Credit Suisse | Outperform |
| Oct-23-18 | Initiated | B. Riley FBR | Buy |
| Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
| Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-14-17 | Resumed | Jefferies | Buy |
| Sep-15-16 | Reiterated | ROTH Capital | Buy |
| Aug-05-16 | Downgrade | Stifel | Buy → Hold |
| Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
| Oct-05-15 | Reiterated | ROTH Capital | Buy |
| Sep-02-15 | Initiated | H.C. Wainwright | Buy |
| Jul-10-15 | Resumed | ROTH Capital | Buy |
| May-06-15 | Reiterated | Mizuho | Neutral |
| May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN
TLPH SEC FilingsTalphera Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Review: Will Talphera Inc stock hit new highs in YEAR2026 Technical Overview & Expert Approved Trade Ideas - baoquankhu1.vn
Geopolitics Watch: Is Talphera Incs growth already priced in2026 Buyback Activity & Daily Technical Forecast Reports - baoquankhu1.vn
Ideas Watch: Is Talphera Inc stock a falling knife or bargain buy2026 Pullbacks & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Risk Recap: Will Talphera Inc stock hit new highs in YEAR - baoquankhu1.vn
TALPHERA (TLPH) CEO uses 9,938 shares to cover RSU tax withholding - Stock Titan
Talphera (TLPH) CFO surrenders shares to cover RSU tax bill - Stock Titan
TALPHERA, INC. (TLPH) CMO surrenders 2,118 shares for RSU taxes - Stock Titan
[Form 4] TALPHERA, INC. Insider Trading Activity - Stock Titan
[EFFECT] TALPHERA, INC. SEC Filing - Stock Titan
Trend Recap: Does Talphera Inc stock reflect fundamentalsMarket Growth Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Talphera (NASDAQ: TLPH) registers resale of 639,931 shares and 6.4M warrant shares - Stock Titan
Will Talphera Inc benefit from current market trends2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Rate Cut: Why is Talphera Inc stock going down2026 Institutional Moves & Weekly Watchlist of Top Performers - baoquankhu1.vn
TLPH Should I Buy - Intellectia AI
Fed Meeting: Is Talphera Inc stock overvalued or fairly pricedQuarterly Portfolio Summary & Trade Opportunity Analysis Reports - baoquankhu1.vn
Dow Update: Whats the profit margin of Talphera IncGlobal Markets & Technical Pattern Based Buy Signals - baoquankhu1.vn
Talphera files prospectus for resale of up to 30.9M shares by selling stockholders - MSN
Aug EndMonth: Is Talphera Inc a top pick in the sectorMarket Sentiment Review & Verified Short-Term Trading Plans - baoquankhu1.vn
Angotti buys Talphera (TLPH) shares worth $124,999 By Investing.com - Investing.com Australia
Angotti buys Talphera (TLPH) shares worth $124,999 - Investing.com
Talphera (TLPH) CEO boosts stake with 213,310-share open-market buy - Stock Titan
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 - Bitget
Talphera (TLPH) registers resale of up to 7.04M shares from private placement - stocktitan.net
Talphera (TLPH) Reports Progress in Nafamostat Study and Financi - GuruFocus
Talphera: Q4 Earnings Snapshot - theheraldreview.com
Talphera, Inc. (Formerly AcelRx) 2025 Annual Report: Business Overview, Key Risks, and Regulatory Challenges in Specialty Pharmaceuticals - Minichart
Talphera, Inc. (NASDAQ: TLPH) 2026 Financial Results and Company Information Overview - Minichart
Talphera Q4 2025 & Investor Day Earnings Call Transcript - MarketBeat
Talphera Inc. Q4 & Fiscal 2025 Financial Results: Revenue & Net Loss ReportNews and Statistics - IndexBox
[10-K] TALPHERA, INC. Files Annual Report - Stock Titan
Talphera 2025 10-K: Revenue $0.028M, Net Loss $14.3M - tradingview.com
TLPH: Net loss increased to $14.3M in 2025; urgent capital needs and Nasdaq delisting risk persist - TradingView
Talphera Inc (TLPH) Reports Q4 Earnings - AlphaStreet
Earnings call transcript: Talphera Inc. Q4 2025: Stock Declines Amid Study Delays By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc. Q4 2025: Stock Declines Amid Study Delays - Investing.com India
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - MarketScreener
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Talphera: Fourth Quarter Financial Results Overview - Bitget
TLPH: 50% enrollment milestone reached in NEPHRO CRRT study; $20.4M cash at year-end 2025 - TradingView
Rate Hike: Can Talphera Inc grow without external fundingTake Profit & Comprehensive Market Scan Reports - baoquankhu1.vn
Talphera, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TLPH PE Ratio & Valuation, Is TLPH Overvalued - Intellectia AI
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Street Watch: Can Talphera Inc keep up with sector leaders2026 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Talphera Inc Stock (TLPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Feb 12 '26 |
Buy |
0.81 |
105,364 |
85,587 |
586,954 |
| Aslam Shakil | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.81 |
35,000 |
28,430 |
83,178 |
| Dasu Badri N | Chief Engineering Officer |
Feb 12 '26 |
Buy |
0.81 |
35,000 |
28,430 |
76,230 |
| ASADORIAN RAFFI | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.81 |
45,000 |
36,554 |
91,256 |
1.83%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):